Newron Pharmaceuticals S.p.A. (NP5.DE)
EUR 8.8
(-0.34%)
EUR 8.8
(-0.34%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -11.62 Million EUR | 8.6% |
| 2022 | -13.3 Million EUR | -7.65% |
| 2021 | -12.35 Million EUR | 31.6% |
| 2020 | -18.06 Million EUR | 13.56% |
| 2019 | -20.89 Million EUR | -39.53% |
| 2018 | -14.97 Million EUR | -244.64% |
| 2017 | -4.34 Million EUR | 71.64% |
| 2016 | -15.32 Million EUR | 37.19% |
| 2015 | -24.4 Million EUR | -117.57% |
| 2014 | -11.21 Million EUR | -44.23% |
| 2013 | -7.77 Million EUR | -188.32% |
| 2012 | -2.69 Million EUR | 58.39% |
| 2011 | -6.48 Million EUR | 70.05% |
| 2010 | -21.64 Million EUR | 11.87% |
| 2009 | -24.55 Million EUR | -34.05% |
| 2008 | -18.31 Million EUR | -33.9% |
| 2007 | -13.68 Million EUR | 18.33% |
| 2006 | -16.75 Million EUR | -11.12% |
| 2005 | -15.07 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -7.68 Million EUR | 0.0% |
| 2023 Q2 | -4.34 Million EUR | 0.0% |
| 2023 Q4 | -7.32 Million EUR | 0.0% |
| 2023 FY | -12.15 Million EUR | 8.6% |
| 2022 Q4 | -6.76 Million EUR | 0.0% |
| 2022 Q2 | -6.64 Million EUR | 0.0% |
| 2022 FY | -13.3 Million EUR | -7.65% |
| 2021 Q4 | -4.49 Million EUR | 0.0% |
| 2021 FY | -12.35 Million EUR | 31.6% |
| 2021 Q2 | -7.87 Million EUR | 0.0% |
| 2020 FY | -18.06 Million EUR | 13.56% |
| 2020 Q4 | -9.46 Million EUR | 0.0% |
| 2020 Q2 | -9.96 Million EUR | 0.0% |
| 2019 Q2 | -17.63 Million EUR | -261.77% |
| 2019 Q1 | -4.87 Million EUR | 33.98% |
| 2019 FY | -20.89 Million EUR | -39.53% |
| 2019 Q4 | -8.6 Million EUR | 0.0% |
| 2018 Q1 | -3.65 Million EUR | 43.1% |
| 2018 FY | -14.97 Million EUR | -244.64% |
| 2018 Q4 | -7.38 Million EUR | 0.0% |
| 2018 Q2 | -7.59 Million EUR | -107.6% |
| 2017 Q1 | -1.28 Million EUR | 80.08% |
| 2017 FY | -4.34 Million EUR | 71.64% |
| 2017 Q4 | -6.43 Million EUR | 0.0% |
| 2017 Q2 | 2.33 Million EUR | 281.67% |
| 2016 Q1 | -3.76 Million EUR | 65.21% |
| 2016 Q2 | -8.87 Million EUR | -135.59% |
| 2016 FY | -15.32 Million EUR | 37.19% |
| 2016 Q4 | -6.44 Million EUR | 0.0% |
| 2015 Q1 | -6.24 Million EUR | -44.41% |
| 2015 Q2 | -6.84 Million EUR | -9.56% |
| 2015 Q4 | -10.83 Million EUR | -73.43% |
| 2015 Q3 | -6.24 Million EUR | 8.73% |
| 2015 FY | -24.4 Million EUR | -117.57% |
| 2014 Q4 | -4.32 Million EUR | -61.34% |
| 2014 FY | -11.21 Million EUR | -44.23% |
| 2014 Q2 | -4.76 Million EUR | -77.75% |
| 2014 Q1 | -2.68 Million EUR | 18.39% |
| 2014 Q3 | -2.68 Million EUR | 43.74% |
| 2013 Q3 | -1.92 Million EUR | 19.86% |
| 2013 Q4 | -3.28 Million EUR | -70.36% |
| 2013 Q2 | -2.4 Million EUR | -24.78% |
| 2013 FY | -7.77 Million EUR | -188.32% |
| 2013 Q1 | -1.92 Million EUR | 0.0% |
| 2012 Q1 | -620.25 Thousand EUR | 0.0% |
| 2012 FY | -2.69 Million EUR | 58.39% |
| 2012 Q4 | -1.92 Million EUR | -210.88% |
| 2012 Q3 | -620.25 Thousand EUR | 0.0% |
| 2012 Q2 | -620.25 Thousand EUR | 0.0% |
| 2011 Q2 | -1.6 Million EUR | 0.0% |
| 2011 Q4 | -620.25 Thousand EUR | 61.42% |
| 2011 FY | -6.48 Million EUR | 70.05% |
| 2011 Q1 | -1.6 Million EUR | 0.0% |
| 2011 Q3 | -1.6 Million EUR | 0.0% |
| 2010 Q3 | -5.41 Million EUR | 0.0% |
| 2010 Q4 | -1.6 Million EUR | 70.33% |
| 2010 FY | -21.64 Million EUR | 11.87% |
| 2010 Q1 | -5.41 Million EUR | 0.0% |
| 2010 Q2 | -5.41 Million EUR | 0.0% |
| 2009 Q4 | -5.41 Million EUR | 11.0% |
| 2009 FY | -24.55 Million EUR | -34.05% |
| 2009 Q3 | -6.08 Million EUR | 0.0% |
| 2009 Q2 | -6.08 Million EUR | 0.0% |
| 2009 Q1 | -6.08 Million EUR | 0.0% |
| 2008 Q1 | -4.08 Million EUR | 0.0% |
| 2008 Q4 | -6.08 Million EUR | -48.88% |
| 2008 FY | -18.31 Million EUR | -33.9% |
| 2008 Q2 | -4.08 Million EUR | 0.0% |
| 2008 Q3 | -4.08 Million EUR | 0.0% |
| 2007 FY | -13.68 Million EUR | 18.33% |
| 2007 Q4 | -4.08 Million EUR | -47.51% |
| 2007 Q3 | -2.77 Million EUR | 0.0% |
| 2007 Q2 | -2.77 Million EUR | 0.0% |
| 2007 Q1 | -2.77 Million EUR | 0.0% |
| 2006 Q2 | -4.18 Million EUR | 0.0% |
| 2006 FY | -16.75 Million EUR | -11.12% |
| 2006 Q3 | -4.18 Million EUR | 0.0% |
| 2006 Q1 | -4.18 Million EUR | 0.0% |
| 2006 Q4 | -2.77 Million EUR | 33.81% |
| 2005 FY | -15.07 Million EUR | 0.0% |
| 2005 Q1 | -3.76 Million EUR | 0.0% |
| 2005 Q2 | -3.76 Million EUR | 0.0% |
| 2005 Q3 | -3.76 Million EUR | 0.0% |
| 2005 Q4 | -4.18 Million EUR | -11.12% |
| 2004 Q4 | -3.76 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Redcare Pharmacy NV | -16.73 Million EUR | 30.532% |